Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;154(8):1555-7.
doi: 10.1038/bjp.2008.221. Epub 2008 Jun 16.

Brivaracetam: a rational drug discovery success story

M A Rogawski  1
Affiliations

Brivaracetam: a rational drug discovery success story

M A Rogawski. Br J Pharmacol. 2008 Aug.

Abstract

Levetiracetam, the alpha-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy. Levetiracetam was discovered in 1992 through screening in audiogenic seizure susceptible mice and, 3 years later, was reported to exhibit saturable, stereospecific binding in brain to a approximately 90 kDa protein, later identified as the ubiquitous synaptic vesicle glycoprotein SV2A. A large-scale screening effort to optimize binding affinity identified the 4-n-propyl analogue, brivaracetam, as having greater potency and a broadened spectrum of activity in animal seizure models. Recent phase II clinical trials demonstrating that brivaracetam is efficacious and well tolerated in the treatment of partial onset seizures have validated the strategy of the discovery programme. Brivaracetam is among the first clinically effective AEDs to be discovered by optimization of pharmacodynamic activity at a molecular target.

PubMed Disclaimer

Figures

Figure 1
Figure 1
2-Oxopyrrolidine (γ-butyrolactam) and analogues.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) Proc Natl Acad Sci USA. 1999;96:15268–15273. - PMC - PubMed
    1. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci. 2006;26:1303–1313. - PMC - PubMed
    1. French JA, Brodsky A, von Rosenstiel P, on behalf of the Brivaracetam N01193 Study Group Efficacy and tolerability of 5, 20 and 50 mg/day brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures Epilepsia 200749Suppl 6400(Abstract C.04) - PubMed
    1. Fuks B, Gillard M, Michel P, Lynch B, Vertongen P, Leprince P, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur J Pharmacol. 2003;478:11–19. - PubMed
    1. Gillard M, Fuks B, Lambeng N, Chatelain P, Matagne A.Binding characteristics of brivaracetam, a novel antiepileptic drug candidate Epilepsia 200749Suppl 6317(Abstract 3.186)